envision pharma holdco limited
envision pharma holdco limited Company Information
Company Number
08555733
Next Accounts
Sep 2025
Shareholders
alligent biopharm consulting (europe) limited
Group Structure
View All
Industry
Non-trading company
Registered Address
envision house, 5 north street, horsham, west sussex, RH12 1XQ
Website
www.envisionpharmagroup.comenvision pharma holdco limited Estimated Valuation
Pomanda estimates the enterprise value of ENVISION PHARMA HOLDCO LIMITED at £0 based on a Turnover of £0 and 0.54x industry multiple (adjusted for size and gross margin).
envision pharma holdco limited Estimated Valuation
Pomanda estimates the enterprise value of ENVISION PHARMA HOLDCO LIMITED at £3.3m based on an EBITDA of £766.5k and a 4.24x industry multiple (adjusted for size and gross margin).
envision pharma holdco limited Estimated Valuation
Pomanda estimates the enterprise value of ENVISION PHARMA HOLDCO LIMITED at £0 based on Net Assets of £-20.7m and 1.31x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Envision Pharma Holdco Limited Overview
Envision Pharma Holdco Limited is a live company located in west sussex, RH12 1XQ with a Companies House number of 08555733. It operates in the non-trading company sector, SIC Code 74990. Founded in June 2013, it's largest shareholder is alligent biopharm consulting (europe) limited with a 100% stake. Envision Pharma Holdco Limited is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Envision Pharma Holdco Limited Health Check
There is insufficient data available to calculate a health check for Envision Pharma Holdco Limited. Company Health Check FAQs
0 Strong
0 Regular
2 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Envision Pharma Holdco Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (42)
- Envision Pharma Holdco Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Envision Pharma Holdco Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Envision Pharma Holdco Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Envision Pharma Holdco Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 118.8%, this is a higher level of debt than the average (47.9%)
- - Envision Pharma Holdco Limited
- - Industry AVG
ENVISION PHARMA HOLDCO LIMITED financials
Envision Pharma Holdco Limited's latest turnover from December 2023 is 0 and the company has net assets of -£20.7 million. According to their latest financial statements, we estimate that Envision Pharma Holdco Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 55,764,875 | 45,813,602 | 23,274,725 | ||||||||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | 32,294,969 | 26,910,301 | 12,197,408 | ||||||||
| Gross Profit | 23,469,906 | 18,903,301 | 11,077,318 | ||||||||
| Admin Expenses | 12,594,194 | 11,516,025 | 6,440,874 | ||||||||
| Operating Profit | 766,547 | -491,200 | 11,764 | -38 | -4,461,749 | -4,461,748 | -4,723,360 | -5,038,714 | 10,875,712 | 7,387,276 | 4,636,444 |
| Interest Payable | 4,412,302 | 4,369,616 | 4,604,579 | 4,817,260 | 6,383,913 | 6,038,707 | 3,157,616 | ||||
| Interest Receivable | 23,635 | ||||||||||
| Pre-Tax Profit | -3,645,755 | -4,860,816 | -4,592,815 | -4,817,298 | -4,461,749 | -4,461,748 | -4,723,360 | -5,015,079 | 4,491,799 | 1,348,569 | 1,478,829 |
| Tax | 230 | 4,930 | 332 | -4,600 | -2,952,440 | -2,826,848 | -1,161,040 | ||||
| Profit After Tax | -3,645,755 | -4,860,816 | -4,592,815 | -4,817,068 | -4,456,819 | -4,461,748 | -4,723,028 | -5,019,679 | 1,539,359 | -1,478,279 | 317,789 |
| Dividends Paid | |||||||||||
| Retained Profit | -3,645,755 | -4,860,816 | -4,592,815 | -4,817,068 | -4,456,819 | -4,461,748 | -4,723,028 | -5,019,679 | 1,539,359 | -1,478,279 | 317,789 |
| Employee Costs | 29,423,512 | 27,541,692 | 11,224,594 | ||||||||
| Number Of Employees | 4 | 377 | 330 | 282 | |||||||
| EBITDA* | 766,547 | -491,200 | 11,764 | -38 | -4,461,749 | -4,461,748 | -4,723,360 | -5,038,714 | 15,591,929 | 11,828,975 | 7,222,012 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 1,849,564 | 1,346,510 | 1,639,915 | ||||||||
| Intangible Assets | 57,979,548 | 50,658,157 | 49,351,678 | ||||||||
| Investments & Other | 89,641,116 | 39,956,314 | 42,104,851 | 40,242,962 | 10,410,302 | 6,925,228 | 6,997,046 | 1 | 1 | ||
| Debtors (Due After 1 year) | 772,081 | 772,081 | 1,035,707 | ||||||||
| Total Fixed Assets | 89,641,116 | 39,956,314 | 42,104,851 | 40,242,962 | 10,410,302 | 6,925,228 | 6,997,046 | 60,601,194 | 52,776,748 | 52,027,301 | |
| Stock & work in progress | |||||||||||
| Trade Debtors | 16,629,607 | 12,563,997 | 6,213,066 | ||||||||
| Group Debtors | 20,491,170 | 33,179,411 | 34,963,539 | 51,841,244 | 3,071,059 | 33,818,168 | 34,168,879 | 19,079,960 | |||
| Misc Debtors | 2,577,614 | ||||||||||
| Cash | 5,208,290 | 2,864,594 | 2,468,444 | ||||||||
| misc current assets | |||||||||||
| total current assets | 20,491,171 | 33,179,411 | 34,963,539 | 51,841,244 | 3,071,059 | 33,818,168 | 34,168,880 | 19,079,960 | 21,837,897 | 15,428,591 | 11,259,125 |
| total assets | 110,132,287 | 73,135,726 | 77,068,390 | 92,084,206 | 13,481,361 | 40,743,396 | 41,165,925 | 19,079,960 | 82,439,091 | 68,205,339 | 63,286,425 |
| Bank overdraft | 1 | 1 | 1 | ||||||||
| Bank loan | 2,356,735 | 1,080,227 | 565,783 | ||||||||
| Trade Creditors | 1,100,130 | 400,110 | 142,786 | ||||||||
| Group/Directors Accounts | 99,492,193 | 79,197,089 | 78,832,402 | 88,546,729 | 6,278,794 | 32,569,084 | 28,398,824 | 2,136,364 | |||
| other short term finances | 31,986,738 | 31,986,738 | 32,318,456 | 31,300,064 | |||||||
| hp & lease commitments | |||||||||||
| other current liabilities | 473,449 | 578,015 | 4,600 | 17,468,945 | 11,180,426 | 8,304,516 | |||||
| total current liabilities | 99,492,193 | 79,670,539 | 78,832,402 | 89,124,744 | 38,265,532 | 64,555,822 | 60,717,280 | 33,441,029 | 20,925,812 | 12,660,765 | 9,013,086 |
| loans | 77,390 | 77,390 | 81,551 | 85,318 | 18,637,018 | 21,803,582 | 25,311,115 | ||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | 852,378 | 341,088 | 107,896 | ||||||||
| other liabilities | 31,249,093 | 31,249,093 | 32,929,424 | 34,450,400 | 38,784,572 | 33,983,254 | 28,298,532 | ||||
| provisions | 850,319 | 126,278 | |||||||||
| total long term liabilities | 31,326,484 | 31,326,484 | 33,010,976 | 34,535,719 | 59,124,288 | 56,254,204 | 53,717,544 | ||||
| total liabilities | 130,818,677 | 110,997,023 | 111,843,378 | 123,660,464 | 38,265,532 | 64,555,822 | 60,717,280 | 33,441,029 | 80,050,100 | 68,914,968 | 62,730,630 |
| net assets | -20,686,390 | -37,861,298 | -34,774,988 | -31,576,258 | -24,784,171 | -23,812,427 | -19,551,355 | -14,361,069 | 2,388,992 | -709,629 | 555,795 |
| total shareholders funds | -20,686,390 | -37,861,298 | -34,774,988 | -31,576,257 | -24,784,171 | -23,812,427 | -19,551,354 | -14,361,069 | 2,388,992 | -709,629 | 555,795 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | 766,547 | -491,200 | 11,764 | -38 | -4,461,749 | -4,461,748 | -4,723,360 | -5,038,714 | 10,875,712 | 7,387,276 | 4,636,444 |
| Depreciation | 318,441 | 299,224 | 588,680 | ||||||||
| Amortisation | 4,397,776 | 4,142,474 | 1,996,888 | ||||||||
| Tax | 230 | 4,930 | 332 | -4,600 | -2,952,440 | -2,826,848 | -1,161,040 | ||||
| Stock | |||||||||||
| Debtors | -12,688,241 | -1,784,128 | -16,877,705 | 48,770,185 | -30,747,109 | -350,711 | 15,088,919 | 1,678,273 | 4,065,610 | 3,509,690 | 9,826,387 |
| Creditors | -1,100,130 | 700,021 | 257,324 | 142,786 | |||||||
| Accruals and Deferred Income | -473,449 | 473,449 | -578,015 | 578,015 | -4,600 | -18,316,723 | 6,799,809 | 3,109,102 | 8,412,412 | ||
| Deferred Taxes & Provisions | -850,319 | 724,041 | 126,278 | ||||||||
| Cash flow from operations | 12,981,339 | 1,766,377 | 16,311,454 | -48,191,978 | 26,290,290 | -4,111,037 | -19,816,547 | -26,988,759 | 16,797,750 | 8,985,140 | 4,789,783 |
| Investing Activities | |||||||||||
| capital expenditure | -735,556 | ||||||||||
| Change in Investments | 49,684,801 | -2,148,536 | 1,861,889 | 29,832,660 | 3,485,074 | -71,818 | 6,997,046 | -1 | |||
| cash flow from investments | -735,556 | ||||||||||
| Financing Activities | |||||||||||
| Bank loans | -2,356,735 | 1,276,508 | 514,444 | 565,783 | |||||||
| Group/Directors Accounts | 20,295,104 | 364,687 | -9,714,326 | 82,267,935 | -26,290,290 | 4,170,260 | 26,262,459 | 2,136,364 | |||
| Other Short Term Loans | -31,986,738 | -331,718 | 1,018,392 | 31,300,064 | |||||||
| Long term loans | -4,161 | -3,767 | 85,318 | -18,637,018 | -3,166,564 | -3,507,533 | 25,311,115 | ||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | -1,680,331 | -1,520,976 | 34,450,400 | -38,784,572 | 4,801,318 | 5,684,722 | 28,298,532 | ||||
| share issue | |||||||||||
| interest | -4,412,302 | -4,369,616 | -4,604,579 | -4,817,260 | 23,635 | -6,383,913 | -6,038,707 | -3,157,616 | |||
| cash flow from financing | 36,703,464 | -3,914,914 | -14,449,564 | 78,024,637 | -22,805,216 | 4,039,218 | 26,813,593 | -38,048,644 | -1,913,389 | -3,134,219 | 51,255,820 |
| cash and cash equivalents | |||||||||||
| cash | -5,208,290 | 2,343,696 | 396,150 | 2,468,444 | |||||||
| overdraft | -1 | 1 | |||||||||
| change in cash | -5,208,289 | 2,343,696 | 396,150 | 2,468,443 |
envision pharma holdco limited Credit Report and Business Information
Envision Pharma Holdco Limited Competitor Analysis
Perform a competitor analysis for envision pharma holdco limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in RH12 area or any other competitors across 12 key performance metrics.
envision pharma holdco limited Ownership
ENVISION PHARMA HOLDCO LIMITED group structure
Envision Pharma Holdco Limited has 6 subsidiary companies.
Ultimate parent company
ARDIAN FRANCE SA
#0105910
2 parents
ENVISION PHARMA HOLDCO LIMITED
08555733
6 subsidiaries
envision pharma holdco limited directors
Envision Pharma Holdco Limited currently has 3 directors. The longest serving directors include Mr Joshua Hollis Korth (Dec 2021) and Mr Adam Deutsch (Aug 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Joshua Hollis Korth | England | 50 years | Dec 2021 | - | Director |
| Mr Adam Deutsch | United Kingdom | 54 years | Aug 2024 | - | Director |
| Mr Stanford Rudnick | 41 years | Dec 2024 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
766.5k
-256%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-20.7m
-0.45%
total assets
110.1m
+0.51%
cash
0
0%
net assets
Total assets minus all liabilities
envision pharma holdco limited company details
company number
08555733
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
June 2013
age
12
incorporated
UK
ultimate parent company
accounts
Audit Exemption Subsidiary
last accounts submitted
December 2023
previous names
N/A
accountant
HARTLEY FOWLER LLP
auditor
-
address
envision house, 5 north street, horsham, west sussex, RH12 1XQ
Bank
-
Legal Advisor
IRWIN MITCHELL LLP
envision pharma holdco limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 4 charges/mortgages relating to envision pharma holdco limited. Currently there are 4 open charges and 0 have been satisfied in the past.
envision pharma holdco limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ENVISION PHARMA HOLDCO LIMITED. This can take several minutes, an email will notify you when this has completed.
envision pharma holdco limited Companies House Filings - See Documents
| date | description | view/download |
|---|
